For decades, natural products have been the foundation of pharmaceutical breakthroughs, with over 60% of approved drugs derived from compounds found in nature. Unnatural Products, a LongeVC portfolio company, is advancing this tradition by using AI and synthetic biology to design macrocyclic molecules that mimic nature’s most effective drug compounds while overcoming the limitations of traditional methods.
Founded by UC Santa Cruz alumni Cameron Pye and Joshua Schwochert, the company focuses on creating synthetic molecules that can cross biological barriers, opening new avenues for treatments in challenging areas like cancer and other high-need diseases. Unnatural Products has secured a research collaboration with Merck worth over $220 million, supporting their breakthrough technology as it moves toward clinical application.
By rethinking how natural molecules are modified, Unnatural Products is pushing the boundaries of drug development and helping to translate nature’s potential into innovative treatments.
Learn more about Unnatural Products Inc. and their journey in the recent article in UC Santa Cruz News here.
Founded by UC Santa Cruz alumni Cameron Pye and Joshua Schwochert, the company focuses on creating synthetic molecules that can cross biological barriers, opening new avenues for treatments in challenging areas like cancer and other high-need diseases. Unnatural Products has secured a research collaboration with Merck worth over $220 million, supporting their breakthrough technology as it moves toward clinical application.
By rethinking how natural molecules are modified, Unnatural Products is pushing the boundaries of drug development and helping to translate nature’s potential into innovative treatments.
Learn more about Unnatural Products Inc. and their journey in the recent article in UC Santa Cruz News here.